Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)
Status:
Terminated
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Determining the efficacy, based upon overall survival, of ruxolitinib added to capecitabine
for the treatment of advanced or metastatic pancreatic cancer.